133 related articles for article (PubMed ID: 17345605)
1. Infliximab and the risk of latent viruses reactivation in active Crohn's disease.
Lavagna A; Bergallo M; Daperno M; Sostegni R; Costa C; Leto R; Crocellà L; Molinaro G; Rocca R; Cavallo R; Pera A
Inflamm Bowel Dis; 2007 Jul; 13(7):896-902. PubMed ID: 17345605
[TBL] [Abstract][Full Text] [Related]
2. Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn's disease patients treated with infliximab.
Bellizzi A; Anzivino E; Ferrari F; Di Nardo G; Colosimo MT; Fioriti D; Mischitelli M; Chiarini F; Cucchiara S; Pietropaolo V
J Neurovirol; 2011 Aug; 17(4):303-13. PubMed ID: 21547609
[TBL] [Abstract][Full Text] [Related]
3. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
4. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model.
Scott FI; Osterman MT; McConnell RA; Lorusso M; Aberra F; Kerner C; Lichtenstein GR; Lewis JD
Inflamm Bowel Dis; 2013 Nov; 19(12):2625-33. PubMed ID: 24108113
[TBL] [Abstract][Full Text] [Related]
5. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis.
Torre-Cisneros J; Del Castillo M; Castón JJ; Castro MC; Pérez V; Collantes E
Rheumatology (Oxford); 2005 Sep; 44(9):1132-5. PubMed ID: 15927999
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy.
Reijasse D; Le Pendeven C; Cosnes J; Dehee A; Gendre JP; Nicolas JC; Beaugerie L
Inflamm Bowel Dis; 2004 Mar; 10(2):85-90. PubMed ID: 15168806
[TBL] [Abstract][Full Text] [Related]
8. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-associated lymphoma in Crohn's disease.
Losco A; Gianelli U; Cassani B; Baldini L; Conte D; Basilisco G
Inflamm Bowel Dis; 2004 Jul; 10(4):425-9. PubMed ID: 15475752
[TBL] [Abstract][Full Text] [Related]
10. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J
Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801
[TBL] [Abstract][Full Text] [Related]
12. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France.
Mengelle C; Kamar N; Mansuy JM; Sandres-Sauné K; Legrand-Abravanel F; Miédougé M; Rostaing L; Izopet J
J Med Virol; 2011 Jan; 83(1):132-6. PubMed ID: 21108350
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.
Giannecchini S; Clausi V; Vultaggio A; Macera L; Maggi F; Martelli F; Azzi A; Maggi E; Matucci A
J Neurovirol; 2012 Feb; 18(1):55-61. PubMed ID: 22281875
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
15. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.
Yao K; Gagnon S; Akhyani N; Williams E; Fotheringham J; Frohman E; Stuve O; Monson N; Racke MK; Jacobson S
PLoS One; 2008 Apr; 3(4):e2028. PubMed ID: 18446218
[TBL] [Abstract][Full Text] [Related]
17. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study.
Ling PD; Lednicky JA; Keitel WA; Poston DG; White ZS; Peng R; Liu Z; Mehta SK; Pierson DL; Rooney CM; Vilchez RA; Smith EO; Butel JS
J Infect Dis; 2003 May; 187(10):1571-80. PubMed ID: 12721937
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome.
Seishima M; Yamanaka S; Fujisawa T; Tohyama M; Hashimoto K
Br J Dermatol; 2006 Aug; 155(2):344-9. PubMed ID: 16882173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
